Imagine using a horse's immune system to create a powerful shield against viruses. Scientists extracted specific antibodies from horses that can neutralize the virus, even the tricky new variants. This treatment is given to sick patients to stop the virus from spreading and prevent their lungs from becoming too inflamed.
Vaccines may not work for everyone, and new virus variants often escape existing immunity. There is a critical shortage of approved antiviral therapies for hospitalized patients who do not respond to vaccines.
A clinical validation program for equine-derived F(ab’)2 polyclonal antibodies. This includes the regulatory documentation for CTAs and the execution of Phase IIa/IIb trials.
If you are a biotech drug developer dealing with the rapid emergence of virus variants — this project developed an EMA-authorized equine F(ab’)2 antibody therapy that provides broad neutralization across multiple variants of concern.
If you are a private hospital network dealing with high critical care costs — this project developed a therapeutic solution that expects to reduce ICU admissions by at least 50%.
If you are a government health agency dealing with vaccinated-non-responders — this project developed a passive immunotherapy that fills the gap where vaccines and anti-inflammatory therapies are insufficient.
Based on available project data, specific pricing or cost per dose is not mentioned; however, the project aims to reduce the overall costs of critical care.
The project utilizes Good Manufacturing Practice (GMP) and is coordinated by Fab’entech, an SME specializing in antibody production, suggesting industrial scalability.
Based on available project data, the therapy is described as EMA-authorized, but specific licensing terms for the F(ab’)2 antibodies are not provided.
The immunotherapy is based on EMA-authorized equine neutralizing antibodies and has undergone Clinical Trial Applications (CTA) for phase IIa/IIb trials.
The project period ran from 2021-06-01 to 2023-11-30, with phase 2a clinical trials launched in March 2022.
The consortium is lean and highly specialized, consisting of 5 partners across 4 countries. It is led by an SME (Fab’entech), which ensures a business-oriented approach to production, supported by a 20% industry ratio. The balance of 3 research entities and 1 other organization provides the necessary clinical and virological expertise to move from lab to phase II trials.
Contact Fab’entech in France for licensing and GMP production inquiries.
Contact us to explore partnership opportunities with the EPIC-CROWN-2 consortium.
